1. Home
  2. VCYT vs MIAX Comparison

VCYT vs MIAX Comparison

Compare VCYT & MIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCYT
  • MIAX
  • Stock Information
  • Founded
  • VCYT 2006
  • MIAX 2007
  • Country
  • VCYT United States
  • MIAX United States
  • Employees
  • VCYT N/A
  • MIAX N/A
  • Industry
  • VCYT Medical Specialities
  • MIAX Investment Bankers/Brokers/Service
  • Sector
  • VCYT Health Care
  • MIAX Finance
  • Exchange
  • VCYT Nasdaq
  • MIAX Nasdaq
  • Market Cap
  • VCYT 2.4B
  • MIAX 2.5B
  • IPO Year
  • VCYT 2013
  • MIAX 2025
  • Fundamental
  • Price
  • VCYT $32.43
  • MIAX $35.00
  • Analyst Decision
  • VCYT Buy
  • MIAX
  • Analyst Count
  • VCYT 9
  • MIAX 0
  • Target Price
  • VCYT $39.89
  • MIAX N/A
  • AVG Volume (30 Days)
  • VCYT 1.3M
  • MIAX 2.4M
  • Earning Date
  • VCYT 11-05-2025
  • MIAX 01-01-0001
  • Dividend Yield
  • VCYT N/A
  • MIAX N/A
  • EPS Growth
  • VCYT N/A
  • MIAX N/A
  • EPS
  • VCYT 0.34
  • MIAX 0.02
  • Revenue
  • VCYT $479,129,000.00
  • MIAX $1,255,413,000.00
  • Revenue This Year
  • VCYT $14.19
  • MIAX N/A
  • Revenue Next Year
  • VCYT $9.68
  • MIAX N/A
  • P/E Ratio
  • VCYT $96.53
  • MIAX $1,681.44
  • Revenue Growth
  • VCYT 19.91
  • MIAX 19.63
  • 52 Week Low
  • VCYT $22.61
  • MIAX $28.63
  • 52 Week High
  • VCYT $47.32
  • MIAX $38.44
  • Technical
  • Relative Strength Index (RSI)
  • VCYT 68.26
  • MIAX N/A
  • Support Level
  • VCYT $29.38
  • MIAX N/A
  • Resistance Level
  • VCYT $30.69
  • MIAX N/A
  • Average True Range (ATR)
  • VCYT 1.11
  • MIAX 0.00
  • MACD
  • VCYT 0.15
  • MIAX 0.00
  • Stochastic Oscillator
  • VCYT 93.72
  • MIAX 0.00

About VCYT Veracyte Inc.

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Share on Social Networks: